FY2026 Earnings Estimate for GALT Issued By HC Wainwright

Key Points

• HC Wainwright raised its FY2026 EPS estimate for Galectin Therapeutics to ($0.31) from ($0.41), keeps a "Buy" rating and $11.00 price target, and sees FY2027 EPS at ($0.33), versus a consensus FY2026 loss of ($0.73).
• Galectin posted quarterly EPS of ($0.08), beating estimates of ($0.10) by $0.02, and the stock trades around $2.67 with a market capitalization of roughly $175.8 million.
• Insiders sold 158,460 shares in the last quarter (including January sales by the CFO and CEO), materially reducing some insider stakes but leaving insiders with about 52.6% ownership.

Galectin Therapeutics Inc. (NASDAQ:GALT - Free Report) - Research analysts at HC Wainwright lifted their FY2026 earnings estimates for shares of Galectin Therapeutics in a note issued to investors on Tuesday, March 31st. HC Wainwright analyst M. Keller now forecasts that the company will post earnings of ($0.31) per share for the year, up from their prior estimate of ($0.41). HC Wainwright has a "Buy" rating and a $11.00 price objective on the stock. The consensus estimate for Galectin Therapeutics' current full-year earnings is ($0.73) per share. HC Wainwright also issued estimates for Galectin Therapeutics' FY2027 earnings at ($0.33) EPS.

Galectin Therapeutics (NASDAQ:GALT - Get Free Report) last posted its quarterly earnings results on Monday, March 30th. The company reported ($0.08) earnings per share for the quarter, beating analysts' consensus estimates of ($0.10) by $0.02.

Separately, Weiss Ratings restated a "sell (d-)" rating on shares of Galectin Therapeutics in a report on Thursday, January 22nd. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of "Hold" and a consensus target price of $11.00.

Galectin Therapeutics Trading Down 0.4%

NASDAQ GALT opened at $2.67 on Friday. The stock has a 50-day simple moving average of $2.95 and a 200 day simple moving average of $4.19. The company has a market capitalization of $175.77 million, a PE ratio of -5.56 and a beta of 1.03. Galectin Therapeutics has a 12 month low of $1.12 and a 12 month high of $7.13.

Insider Buying and Selling

In other Galectin Therapeutics news, CFO Jack W. Callicutt sold 20,354 shares of the stock in a transaction dated Tuesday, January 6th. The stock was sold at an average price of $3.67, for a total value of $74,699.18. Following the completion of the sale, the chief financial officer directly owned 7,614 shares in the company, valued at $27,943.38. This represents a 72.78% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Joel Lewis sold 37,698 shares of the firm's stock in a transaction dated Tuesday, January 6th. The stock was sold at an average price of $3.58, for a total value of $134,958.84. Following the sale, the chief executive officer directly owned 832,592 shares in the company, valued at approximately $2,980,679.36. This represents a 4.33% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 158,460 shares of company stock valued at $596,165. 52.60% of the stock is owned by company insiders.

Hedge Funds Weigh In On Galectin Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of GALT. Vanguard Group Inc. lifted its stake in Galectin Therapeutics by 2.9% in the third quarter. Vanguard Group Inc. now owns 2,247,967 shares of the company's stock valued at $9,520,000 after buying an additional 63,419 shares in the last quarter. Osaic Holdings Inc. lifted its position in Galectin Therapeutics by 3.4% in the 2nd quarter. Osaic Holdings Inc. now owns 1,265,384 shares of the company's stock valued at $2,670,000 after acquiring an additional 41,968 shares in the last quarter. Jane Street Group LLC acquired a new position in Galectin Therapeutics in the 2nd quarter worth $1,580,000. Marshall Wace LLP boosted its stake in Galectin Therapeutics by 8.6% in the 4th quarter. Marshall Wace LLP now owns 602,134 shares of the company's stock worth $2,505,000 after purchasing an additional 47,873 shares during the period. Finally, Wealthspire Advisors LLC increased its holdings in Galectin Therapeutics by 25.5% during the 4th quarter. Wealthspire Advisors LLC now owns 601,973 shares of the company's stock worth $2,504,000 after purchasing an additional 122,455 shares in the last quarter. 11.68% of the stock is currently owned by institutional investors and hedge funds.

About Galectin Therapeutics

Galectin Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel therapies that target galectin proteins, which are implicated in fibrotic, inflammatory and malignant diseases. The company's lead product candidate, belapectin (formerly GR-MD-02), is a galectin-3 inhibitor being evaluated in Phase 2 clinical trials for nonalcoholic steatohepatitis (NASH) with cirrhosis. In addition to its core pipeline in fibrotic liver disease, Galectin Therapeutics continues to explore the potential of its galectin inhibitors in oncology and other indications driven by abnormal tissue remodeling.

Founded in 2000, the company is headquartered in Norcross, Georgia, where it oversees discovery research, preclinical studies and clinical trial coordination.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.